Literature DB >> 31402235

Evaluation of infection rates with narrow versus broad-spectrum antibiotic regimens in civilian gunshot open-fracture injury.

Jordan A Woolum1, Abby M Bailey2, Adam Dugan3, Rahul Agrawal4, Regan A Baum2.   

Abstract

INTRODUCTION: Civilian gunshot open-fracture injuries portray a significant health burden to patients. Use of antibiotics is endorsed by guideline recommendations for the prevention of post-traumatic infections, however, antimicrobial selection and their associated outcomes remains unclear. Therefore, we sought to compare infectious and other clinical outcomes between three antimicrobial cohorts in patients with gunshot-related fractures requiring operative intervention.
MATERIALS AND METHODS: Patients were identified by retrospectively querying the University of Kentucky Trauma Registry for gunshot wound victims. A narrow regimen, an expanded gram-negative regimen, and a regimen containing a fluoroquinolone antimicrobial were identified for comparison. The primary outcome was a composite of infections at or before 14 days of hospitalization. Secondary endpoints included hospital length of stay, incidence of multidrug resistant bacteria and methicillin-resistant Staphylococcus aureus colonization, number of drug-related adverse events, number of Clostridium difficile infections, and 30-day mortality.
RESULTS: 252 patients were selected for inclusion: 126 in the narrow regimen, 49 in the expanded gram-negative regimen, and 77 in the fluoroquinolone-based regimen. There were no statistical differences in the primary endpoint of early infectious outcomes between groups (p = 0.1797). The expanded gram-negative regimen was associated with increased hospital length of stay, and increased incidence of multi-drug resistant bacteria and methicillin-resistant Staphylococcus aureus colonization. There were no statistically significant differences in any of the remaining secondary endpoints.
CONCLUSION: In this study evaluating civilian gunshot trauma, broad spectrum antibiotic coverage was not associated with improvements in post-traumatic infections. A randomized trial is needed to confirm these results.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial; Fracture; Gunshot; Open; Prophylaxis

Mesh:

Substances:

Year:  2019        PMID: 31402235      PMCID: PMC6980938          DOI: 10.1016/j.ajem.2019.158358

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  22 in total

1.  Methicillin-resistant Staphylococcus aureus in a teaching hospital: investigation of nosocomial transmission using a matched case-control study.

Authors:  G Dziekan; A Hahn; K Thüne; G Schwarzer; K Schäfer; F D Daschner; H Grundmann
Journal:  J Hosp Infect       Date:  2000-12       Impact factor: 3.926

Review 2.  Infection in conflict wounded.

Authors:  W G P Eardley; K V Brown; T J Bonner; A D Green; J C Clasper
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-01-27       Impact factor: 6.237

Review 3.  Surgical Infection Society guideline: prophylactic antibiotic use in open fractures: an evidence-based guideline.

Authors:  Carl J Hauser; Charles A Adams; Soumitra R Eachempati
Journal:  Surg Infect (Larchmt)       Date:  2006-08       Impact factor: 2.150

Review 4.  Current orthopaedic treatment of ballistic injuries.

Authors:  David A Volgas; James P Stannard; Jorge E Alonso
Journal:  Injury       Date:  2005-03       Impact factor: 2.586

5.  Gunshot-induced fractures of the extremities: a review of antibiotic and debridement practices.

Authors:  Vasanth Sathiyakumar; Rachel V Thakore; Daniel J Stinner; William T Obremskey; James R Ficke; Manish K Sethi
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

Review 6.  Guidelines for the prevention of infections associated with combat-related injuries: 2011 update: endorsed by the Infectious Diseases Society of America and the Surgical Infection Society.

Authors:  Duane R Hospenthal; Clinton K Murray; Romney C Andersen; R Bryan Bell; Jason H Calhoun; Leopoldo C Cancio; John M Cho; Kevin K Chung; Jon C Clasper; Marcus H Colyer; Nicholas G Conger; George P Costanzo; Helen K Crouch; Thomas K Curry; Laurie C D'Avignon; Warren C Dorlac; James R Dunne; Brian J Eastridge; James R Ficke; Mark E Fleming; Michael A Forgione; Andrew D Green; Robert G Hale; David K Hayes; John B Holcomb; Joseph R Hsu; Kent E Kester; Gregory J Martin; Leon E Moores; William T Obremskey; Kyle Petersen; Evan M Renz; Jeffrey R Saffle; Joseph S Solomkin; Deena E Sutter; David R Tribble; Joseph C Wenke; Timothy J Whitman; Andrew R Wiesen; Glenn W Wortmann
Journal:  J Trauma       Date:  2011-08

7.  Ciprofloxacin inhibition of experimental fracture healing.

Authors:  P M Huddleston; J M Steckelberg; A D Hanssen; M S Rouse; M E Bolander; R Patel
Journal:  J Bone Joint Surg Am       Date:  2000-02       Impact factor: 5.284

8.  Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro.

Authors:  P D Holtom; S A Pavkovic; P D Bravos; M J Patzakis; L E Shepherd; B Frenkel
Journal:  J Orthop Res       Date:  2000-09       Impact factor: 3.494

Review 9.  A civilian perspective on ballistic trauma and gunshot injuries.

Authors:  Philipp Lichte; Reiner Oberbeck; Marcel Binnebösel; Rene Wildenauer; Hans-Christoph Pape; Philipp Kobbe
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-06-17       Impact factor: 2.953

10.  Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia.

Authors:  Swati Patolia; Getahun Abate; Nirav Patel; Setu Patolia; Sharon Frey
Journal:  Ther Adv Infect Dis       Date:  2017-09-12
View more
  1 in total

1.  Early outcomes of surgically managed civilian gunshot femur fractures at a level one trauma unit in Cape Town, South Africa: a retrospective review.

Authors:  Obakeng Makhubalo; Marilize Burger; Shafique Jakoet; Marcus Van Heukelum; Nicholas le Roux; Muaad Gerafa; Simone Van der Merwe; Nando Ferreira
Journal:  Eur J Trauma Emerg Surg       Date:  2022-10-18       Impact factor: 2.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.